Overview

Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy

Status:
Terminated

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether TAC-101 as a second line therapy for patients who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular carcinoma. The study is also looking at the safety of TAC-101 following treatment with Sorafenib.

Phase:

Phase 2

Details

Lead Sponsor:

Taiho Oncology, Inc.

Collaborator:

Quintiles, Inc.

Treatments:

Sorafenib